Exchange rates and rabeprazole dull Eisai's first half
This article was originally published in Scrip
Executive Summary
Global sales of Eisai's top product, the Alzheimer's disease therapy Aricept (donepezil), edged up by 2% to ¥156.0 billion ($1.73 billion) in the first half, despite the effects of the strong yen on sales outside Japan.